Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Vaccine to protect a pig against actinobacillus pleuropneumoniae

一种胸膜肺炎、放线杆菌的技术，应用在针对胸膜肺炎放线杆菌保护猪的疫苗领域，能够解决没有显示出猪保护作用等问题

Pending Publication Date: 2020-08-07
INTERVET INT BV
View PDF5 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, it has not been shown to protect pigs, let alone produce comparable levels of protection to commercially available vaccines against APP

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Vaccine to protect a pig against actinobacillus pleuropneumoniae
  • Vaccine to protect a pig against actinobacillus pleuropneumoniae

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0022] Embodiment 1: the recombinant expression of ApxI

[0023] Construction of transfer vector pFastbac-ApxIA

[0024] The rApxIA gene was synthesized based on Actinobacillus pleuropneumoniae strain 4074 (Swissprot accession number: P55128). The gene was codon-optimized for baculovirus polyhedrin usage and included a Kozak sequence (TATAAAT) and a 3' hexahistidine tag. The rApxIA-His gene was cloned behind the polyhedrin promoter of plasmid pFastbac1 (Life Technologies, Carlsbad, USA) as a BamHI fragment to obtain plasmid pFastbac-ApxIA TAT.

[0025] Production of Recombinant Baculovirus BacdCCApxIA-TAT

[0026] Recombinant baculoviruses were produced in the Bac to Bac system (Life Technologies, Carlsbad, USA) using the plasmids described above according to the manufacturer's protocol. The E. coli cells used for transformation contained the parental baculovirus and had chitinase and v-cathepsin gene deletions (Kaba SA, Salcedo AM, Wafula PO, Vlak JM, van Oers MM. J Virol ...

Embodiment 2

[0030] Example 2: Vaccine Effectiveness

[0031] Vaccine preparation

[0032] Two different vaccines were prepared for the study. The first vaccine comprises purified baculovirus expressing ApxI as obtained using the method described in Example 1. A second vaccine versus a commercially available vaccine as a positive control APP is comparable, comprising ApxI and ApxII purified from the culture supernatant of A. pleuropneumoniae (and thus complexed with LPS), also known as "native ApxI+ApxII". Investigational vaccines differ from commercially available vaccines APP because it does not contain the ApxIII toxin. However, this was irrelevant for challenge with serotype 10 field strains (serotype 10 does not produce ApxIII). Antigens were mixed with mineral oil-containing adjuvant (XSolve, available from MSD AnimalHealth, Boxmeer, The Netherlands) at a final concentration of 25 μg / ml of each antigen.

[0033] vaccination program

[0034] 3 groups of 8 piglets from an A. p...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention pertains to a vaccine to protect a pig against an infection with Actinobacillus pleuropneumoniae, the vaccine comprising an RTX toxin of Actinobacillus pleuropneumoniae recombinantly expressed by a baculovirus, and a pharmaceutically acceptable carrier.

Description

technical field [0001] In general, the present invention relates to a vaccine that protects pigs against Actinobacillus pleuropneumoniae infection. Background technique [0002] The present invention relates to a vaccine against porcine pleuropneumonia, a worldwide disease causing significant economic losses to the pig industry. The causative agent of swine pleuropneumoniae is Actinobacillus pleuropneumoniae (APP), a Gram-negative bacterium belonging to the family Pasteurellaceae. The disease is transmitted by the aerosol route or by direct contact with infected pigs and is characterized by haemorrhage, fibrosis, and necrotizing lung lesions. Clinical manifestations can range from hyperacute to chronic, and asymptomatic carrier pigs can spread the disease when introduced into uninfected herds. Fifteen serotypes have been described based on capsular polysaccharide and lipopolysaccharide (LPS) O-chain components. Serotyping and other genotyping methods for A. pleuropneumoni...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/102C12N15/866A61K39/00
CPCA61K39/102C12N15/866A61K2039/552A61P31/04A61K2039/54A61K2039/55544C07K14/285
Inventor M·H·威特夫莱特J·J·E·比杰斯玛
Owner INTERVET INT BV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com